Moderna Posts $1.97 Q2 Loss Per Share, Norovirus Vaccine Fails Phase 3
MRNA has more than doubled off its 52-week low of $22.28.
Summary
Moderna reported a Q2 loss of $1.97 per share, with revenue of $145M and a net loss of $0.8B. The quarter was marred by the failure of its norovirus vaccine candidate in a Phase 3 trial, a significant pipeline setback. This follows a Q1 that saw strong revenue but a large net loss due to a patent settlement charge. The norovirus failure raises questions about the broader mRNA platform beyond COVID and flu, where the company has seen recent regulatory progress. Investors will focus on the cash burn rate and whether upcoming catalysts like the mFlusiva flu vaccine approval can offset this disappointment.
Updates
· Dow Jones Newswires — Shares fell 7.2% premarket despite the beat. Moderna reiterated full-year guidance of 10% revenue growth, with 55% of H2 revenue expected in Q3. Spikevax sales were buoyed by UK deliveries, masking declines in the US and South America.
· SEC 8-K — Moderna improved its 2026 GAAP operating expense outlook by about $0.2 billion and now projects year-end cash of $4.7–5.2 billion. It also expects potential approval of mFLUSIVA with an August 5 PDUFA date.
At the time of this announcement, MRNA was trading at $55.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23B. The 52-week trading range was $22.28 to $85.60. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.